Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering
Article content
ZUG, Switzerland — Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 2.38 million shares at a price of CHF 97.75 per share for a total consideration of CHF 232.5 million in the context of the accelerated bookbuild offering ('ABO') of Galderma shares by Sunshine SwissCo GmbH ('EQT'), Abu Dhabi Investment Authority and Auba Investment Pte. Ltd. launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering.
Article content
The repurchase, which is expected to settle on June 2, is being financed by Galderma's existing liquidity on hand and will not affect the company's ability to deliver on its strategic and financing priorities.
Article content
The shares will be held in treasury for future use in connection with Galderma's employee participation plans, business development opportunities and/or treasury management.
Article content
Following the closing of the ABO, the free float in Galderma's shares is expected to increase from 41.8% to 49.8%.
Article content
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
Article content
Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as 'plans', 'targets', 'aims', ' believes', 'expects', 'anticipates', 'intends', 'estimates', 'will', 'may', 'continues', 'should' and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma's markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
For further information:
Article content
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Article content
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Article content
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
$77.8 Million in Revenue Through April 2025, Confirms Full-Year Guidance and Fast-Track to 400 Million Run Rate and $1 Billion Target After Key Fintech Acquisition: iQSTEL, Inc. (Nasdaq: IQST)
$IQST Current Plans Include $1 Million Subsidiary Sale with Stock Dividend to Shareholders Diversified Business with Divisions Focused on Telecommunications, Fintech, Electric Vehicles, Artificial Intelligence and More. Organic Growth, Acquisitions and High-Margin Product Expansion. New Rebrand Program with Expansion into Fintech, AI and Cybersecurity to Address Challenges Across Multiple Industries. Completed 11 Acquisitions Since 2018 and Actively Pursuing More. Accelerating Rollout of Cutting-Edge eSIM and Roaming Connectivity Services. Preliminary Net Revenue for First Four Months of 2025 Totaled Approximately $77.8 Million. $57.6M Q1 Revenue Reaffirms Path to $1 Billion by 2027. $11.6 Million in Stockholders' Equity or $4.38 Per Common Share. Successful NASDAQ Uplisting with No Capital Raise or Shareholder Dilution. Definitive Agreement to Acquire 51% of GlobeTopper fintech innovator with operations across America, Europe, and Africa, Effective July 1, 2025. MOU for Strategic Sale of BChain Subsidiary to Accredited Solutions, Inc. (ASII). IQST Shareholders to Receive ASII Common Shares as a Dividend as Part of Nasdaq Uplisting Plan. iQSTEL, Inc. (Nasdaq: IQST) offers cutting-edge solutions in Telecom, Fintech, Blockchain, Artificial Intelligence (AI), and Cybersecurity. Operating in 21 countries, IQST delivers high-value, high-margin services to its extensive global customer base. IQST projects $340 million in revenue for FY-2025, building on its strong business platform. IQST has been building a strong business platform with its customers, selling them millions of dollars per month, and by leveraging this trust, the company is now beginning to sell high-tech, high-margin products across its divisions. IQST is strategically positioned to achieve $1 billion in revenue by 2027 through organic growth, acquisitions, and high-margin product expansion. Preliminary $77.8 Million in Revenue Through April 2025 -- Confirms Full-Year Guidance and Fast-Track to $400M Run Rate On June 5th IQST announced that its preliminary net revenue for the first four months of 2025 totaled approximately $77.8 million, continuing the company's strong growth momentum and reinforcing its confidence in full-year revenue guidance. This preliminary figure reflects a 12% increase compared to the same period in 2024, highlighting the strength and consistency of IQST organic growth across its core telecom operations. IQST operating business anticipates generating over $3 million in adjusted EBITDA in 2025, with positive net income in the seven-digit range, driven by operational efficiencies, scalability, and its increasing focus on high-margin services. IQST continues to execute its strategic roadmap to become a $1 billion revenue company by 2027, combining organic growth, targeted acquisitions, and expansion in key technology sectors, including cybersecurity, AI, managed services, and fintech. The recent IQST uplisting to NASDAQ has already begun to catalyze momentum. The increased visibility and credibility among institutional investors are expected to unlock new strategic opportunities and financial partnerships. Rapid Global Fintech Expansion with GlobeTopper Acquisition — Fast-Tracking $1 Billion Growth Plan On May 29th IQST announced the execution of a definitive agreement to acquire 51% of GlobeTopper ( — a dynamic fintech innovator with operations across America, Europe, and Africa. The transaction becomes effective July 1, 2025. GlobeTopper's strong market positioning is evident in its current standalone performance — planning to generate over $65 million in profitable revenue in 2025 alone. Its financial outlook for the next three years reflects steady growth and operational momentum. The IQST goal is to take GlobeTopper's innovative fintech products and services and scale them globally through IQSTEL's powerful commercial platform — which already reaches over 600 of the largest telecom operators around the world. In parallel, GlobeTopper's existing client base — including prominent multinational brands — opens the door for IQST to expand its reach into new sectors, allowing deeper penetration into the enterprise and global brand markets. Together, IQST and GlobeTopper plan lead the next wave of convergence between fintech and telecommunications in high-value markets across Africa, Europe, and the Americas. As part of the transaction, Craig Span will continue in his role as CEO of GlobeTopper, ensuring leadership continuity and seamless integration into the IQST Fintech Division. GlobeTopper will collaborate with co-developing a 3-year business plan to position itself as a top-tier player in the global fintech ecosystem. The deal puts IQST firmly on track to reach a $400 million revenue run rate and achieve a targeted 80% telecom / 20% tech revenue mix by the end of this year. This acquisition strengthens the IQST position as a high-margin, tech-focused growth platform, advancing its $1 billion revenue goal by 2027. Additionally, IQST plans to invest up to $1.2 million over the next 2 yearsto accelerate GlobeTopper's growth and product roadmap. Follow-Up Shareholder Letter Highlighting NASDAQ Benefits, $57.6M Q1 Revenue, and $14.58 Assets Per Share on Path to $1 Billion On May 20th IQST issued a follow-up shareholder letter to reinforce the strategic value of its recent NASDAQ uplisting and to highlight the company's most important operational and financial metrics. IQST has celebrated its official listing on the NASDAQ Capital Market, a transformational milestone that opens the door to unprecedented commercial, financial, and strategic opportunities. IQST management has now prepared a new Shareholder Letter summarizing the most critical indicators of IQSTEL's financial strength and long-term growth potential. Key Shareholder Takeaways: Current Assets Per Share (Q1 2025): $14.58 Current Revenue Per Share: Over $100 Current Stockholders' Equity Per Share (Q1 2025): $4.38 Current Outstanding Shares: 2.9 million Current Market Cap: 0.10x our Revenue in 2024 Q1 2025 Revenue: $57.6M 2025 Revenue Forecast: $340 million Year-End Run Rate Goal: $400 million Year-End Revenue Mix Goal: 80% Telecom / 20% Tech Services Countries of Commercial Footprint : 21 Employees: 100+ Business Relationships: 600+ global interconnections Telecom Division (99% revenue stream): Positive Adjusted EBITDA and Positive Net Income now supports IQST again for European-based investors What IQST Shareholders Can Expect as a NASDAQ Company 1. Institutional Access & Global Liquidity IQST is now available to institutional funds and platforms like in the UK and Europe. Global retail and institutional investors can participate more easily. 2. Commercial Trust and Growth Acceleration IQST already handles hundreds of millions in B2B telecom transactions annually. NASDAQ status boosts credibility with customers and partners—catalyzing growth. 3. Shareholder-Friendly Capital Structure Fewer than 2.9 million shares outstanding. No capital raise or dilution for the NASDAQ uplisting. All convertibles mature in Q1 2026—no short-term pressure. 4. Revaluation Opportunity IQST trades at ~0.10x 2024 revenue. NASDAQ peers in telecom/tech often trade at 1.0x or more—even without profitability. Strong M&A Capability IQST stock is now a more attractive currency for acquiring EBITDA-positive businesses. IQST is actively targeting strategic acquisitions in telecom, fintech, AI, and cybersecurity. With a scalable model, a trusted global platform, and momentum from the NASDAQ listing, IQST believes the following objectives are well within reach: Revenue: $340 million Adjusted EBITDA (Operating Subsidiaries): $3 million+ Net Income (Operating Subsidiaries): 7-digit Year-End Revenue Run Rate: $400 million Year-End Revenue Mix Goal: 80% Telecom / 20% Tech Strategic Acquisitions: Targeting companies with positive EBITDA and synergy potential Built for the Future IQST is now leveraging its trusted telecom platform to deliver: High Tech Telecom Services: eSIM, roaming, numbering Fintech Services: remittance, mobile banking AI-Driven Customer Platforms: automation, support, lead generation Cybersecurity Solutions: tailored for telecom operators and infrastructure clients IQST Reports $57.6M Q1 Revenue in First NASDAQ Shareholder Letter, Reaffirms Path to $1 Billion by 2027 as Global Tech Evolution Accelerates On May 15th IQST released its Q1 2025 Shareholder Letter—its first since being uplisted to the NASDAQ Capital Market. In the letter, CEO Leandro Iglesias detailed the company's performance, strategic vision, and transformation into a high-tech multinational on course to reach $1 billion in annual revenue by 2027. Over the past seven years, I QST has consistently delivered on every major commitment to shareholders including: Sustained Revenue Growth: From $13.8 million in 2018 to $283 million in 2024, consistently meeting or exceeding annual forecasts. Robust Corporate Governance: Fully established Audit, Compensation, and Ethics Committees; an independent Board of Directors; and annual shareholder meetings supporting transparency and accountability. IQST Uplisting from Pink to QB to OTCQX, culminating in a NASDAQ listing in 2025—with no capital raise or shareholder dilution. Enhanced Shareholder Value: Revenue Per Share now exceeds $100, reflecting disciplined growth and execution. Equity Growth: IQST net stockholders' equity improved from ($1.6 million) or -$0.11 per share in 2018 to $11.6 million or $4.38 per common share as of March 31, 2025—a powerful indicator of the value we've created over time. IQST business has now reached critical mass in terms of infrastructure, scale, and market presence. With over 100 employees operating across more than 20 countries, and 600+ business relationships involving direct network interconnections, IQST has built a platform that is both robust and difficult to replicate. This unique foundation positions IQST to introduce and scale high-margin, high-tech services including: High Tech Telecom Solutions: eSIM, roaming, and cloud numbering Fintech Services: digital payments and mobile banking AI Telecom Services: automation, customer support, lead generation Cybersecurity Services: enterprise-grade telecom infrastructure protection The IQST 2025 roadmap is focused on profitable growth, operational scale, and long-term value creation: For more information on $IQST visit: Disclosure listed on the CorporateAds website Media Contact Company Name: IQSTEL Inc. Contact Person: Leandro Jose Iglesias, President and CEO Email: Send Email Phone: +1 954-951-8191 Address: 300 Aragon Avenue Suite 375 City: Coral Gables State: Florida 33134 Country: United States Website:
Globe and Mail
8 hours ago
- Globe and Mail
Novo Nordisk Stock: Is It Still a Smart Buy?
Much like the long-term users of its most popular product, Novo Nordisk 's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. An increasingly crowded field Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Fragmentation and setbacks Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Fighting back Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor 's total average return is789% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
National Post
10 hours ago
- National Post
SES Announces Appointment of New CFO
Article content Elisabeth Pataki, a progressive finance executive with over 20 years of experience at Article content SES's Leadership Team as new CFO Article content LUXEMBOURG — SES today announced its Board of Directors has appointed Elisabeth (Lisa) Pataki as Chief Financial Officer (CFO), effective 16 June 2025. Lisa is a progressive finance executive with over 20 years of experience at various publicly listed multi-national aerospace and defence companies with strong background in company transformation and investment strategies. She will succeed Sandeep Jalan who has been SES's CFO since May 2020. Article content The SES Board acknowledges Sandeep's contribution to SES and wishes him success in future endeavours. Lisa will work closely with Sandeep to ensure a smooth handover before he leaves on 31 July 2025. Article content 'I would like to thank Sandeep for his steadfast leadership over the last five years where he has driven continuous execution improvement and transformation while strengthening the company's balance sheet with a competitive cost of capital and delivering healthy cash returns to shareholders,' said Adel Al-Saleh, CEO of SES. 'We are pleased to welcome Lisa as our new CFO. Lisa has extensive experience in the aerospace and defence ecosystem and has completed several successful M&A finance integrations. Moreover, her ability to develop financial strategies that prioritise operational focus, efficiency, and profitable investments will strengthen SES's Leadership Team, helping SES achieve our mission of being a leading satellite player.' Article content 'I would like to thank everyone at SES for their outstanding teamwork,' said Sandeep, CFO of SES. 'I am proud of the strides we have made during the past years, and I will continue to cheer SES's progress in the industry.' Article content Incoming CFO Lisa said, 'I look forward to stepping into this new position and working with everyone at SES to jointly deliver an exciting future for the years to come.' Article content Lisa joins SES from Aerojet Rocketdyne, an L3Harris Company, where she helped expand profitability through streamlining operations and prioritising capital investments for long-term growth. As Group CFO for the Comet Group from 2020-2023, she drove EBITDA margin expansion of over 5 percentage points. In her 10-year progressive career (2005-2015) across RTX Corporation (formerly Raytheon Technologies Corporation), she held multiple finance roles and led the financial integration of Applied Signal Technologies, one of Raytheon's largest acquisitions in 2011. Article content Twitter Article content | Article content Facebook Article content | Article content YouTube Article content | Article content LinkedIn Article content | Article content Instagram Article content Article content Article content Visit the Media Gallery > Article content About SES Article content SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous earth orbit (GEO) fleet and medium earth orbit (MEO) constellation of satellites, offering a combination of global coverage and high-performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: Article content Article content Contacts Article content
